COMPLAINT FOR PHARMACEUTICAL PRODUCT LIABILITY

IN THE [________________________________] COURT

[________________________________] COUNTY, STATE OF [________________________________]

---

Case No.: [________________________________]

PLAINTIFF:
[________________________________]

v.

DEFENDANT(S):
[________________________________] (Manufacturer)
[________________________________] (Distributor)
[________________________________] (Retailer/Pharmacy)

---

COMPLAINT FOR DAMAGES - PHARMACEUTICAL PRODUCT LIABILITY

Plaintiff [________________________________], by and through undersigned counsel, brings this Complaint against Defendants and alleges:

---

I. INTRODUCTION

1. This is an action for damages arising from Defendants' design, manufacture, marketing, and sale of the prescription drug [________________________________] (the "Drug"). The Drug caused serious injuries to Plaintiff, including [________________________________], due to its defective and unreasonably dangerous nature.

---

II. PARTIES

Plaintiff

2. Plaintiff [________________________________] is an individual residing at [________________________________], County of [________________________________], State of [________________________________].

3. At all relevant times, Plaintiff was prescribed and took the Drug as directed by Plaintiff's physician.

Defendants

4. Defendant [________________________________] ("Manufacturer") is a pharmaceutical company organized under the laws of [________________________________], with its principal place of business at [________________________________]. Manufacturer designed, developed, tested, manufactured, labeled, marketed, distributed, and sold the Drug.

5. Defendant [________________________________] ("Distributor") is a [________________________________] organized under the laws of [________________________________], with its principal place of business at [________________________________]. Distributor distributed and sold the Drug.

6. Defendant [________________________________] ("Pharmacy/Retailer") is a [________________________________] organized under the laws of [________________________________], with its principal place of business at [________________________________]. Pharmacy dispensed the Drug to Plaintiff.

---

III. JURISDICTION AND VENUE

7. This Court has subject matter jurisdiction pursuant to [________________________________].

8. The amount in controversy exceeds $[________________________________], exclusive of interest and costs.

9. This Court has personal jurisdiction over Defendants because:
   ☐ Defendants conduct substantial business in this State
   ☐ Defendants sold the Drug in this State
   ☐ Plaintiff's injuries occurred in this State
   ☐ Other: [________________________________]

10. Venue is proper in this County pursuant to [________________________________].

---

IV. FACTUAL ALLEGATIONS

A. The Drug

11. The Drug known as [________________________________] (generic name: [________________________________]) is a prescription medication manufactured by Defendant Manufacturer.

12. The Drug is prescribed to treat [________________________________].

13. The Drug was approved by the U.S. Food and Drug Administration (FDA) on or about [__/__/____] under New Drug Application (NDA) #[________________________________].

14. The Drug is classified as [________________________________] and is marketed under the trade name(s) [________________________________].

B. Plaintiff's Use of the Drug

15. On or about [__/__/____], Plaintiff was diagnosed with [________________________________] by [________________________________], M.D.

16. On or about [__/__/____], Dr. [________________________________] prescribed the Drug to Plaintiff.

17. Plaintiff filled the prescription at [________________________________] Pharmacy.

18. Plaintiff took the Drug as prescribed, including:
    - Dosage: [________________________________]
    - Frequency: [________________________________]
    - Duration: From [__/__/____] to [__/__/____]

19. Plaintiff followed all instructions provided with the Drug.

20. Plaintiff was not informed by Defendants or the prescribing physician of the risk of [________________________________].

C. The Defect and Known Risks

21. The Drug is defective and unreasonably dangerous because:

☐ Design Defect:
The Drug's chemical composition and/or formulation creates unreasonable risks of harm that outweigh its therapeutic benefits.

☐ Manufacturing Defect:
The Drug was not manufactured according to FDA-approved specifications and/or Good Manufacturing Practice (GMP) requirements.

☐ Failure to Warn:
The Drug's labeling failed to adequately warn of the risk of [________________________________].

22. Defendants knew or should have known of the following risks associated with the Drug:
    ☐ [________________________________]
    ☐ [________________________________]
    ☐ [________________________________]
    ☐ [________________________________]

23. Defendants' knowledge of these risks is evidenced by:
    ☐ Pre-clinical testing data
    ☐ Clinical trial data
    ☐ Post-marketing surveillance data
    ☐ Adverse Event Reports submitted to FDA
    ☐ Scientific literature and studies
    ☐ Internal company documents
    ☐ Foreign regulatory warnings
    ☐ Other: [________________________________]

D. Defendants' Wrongful Conduct

24. Despite knowledge of the Drug's risks, Defendants:

☐ Failed to conduct adequate pre-market testing
☐ Concealed adverse testing data from the FDA
☐ Provided incomplete information to the FDA
☐ Failed to include adequate warnings on the Drug's label
☐ Failed to update the Drug's label when new risks emerged
☐ Failed to provide adequate warnings to prescribing physicians
☐ Engaged in off-label marketing and promotion
☐ Minimized known risks in marketing materials
☐ Failed to implement a Risk Evaluation and Mitigation Strategy (REMS)
☐ Failed to report adverse events to the FDA in a timely manner
☐ Other: [________________________________]

E. Plaintiff's Injuries

25. As a direct and proximate result of taking the Drug, Plaintiff developed:
    ☐ [________________________________]
    ☐ [________________________________]
    ☐ [________________________________]
    ☐ [________________________________]

26. Plaintiff's injuries were first diagnosed on or about [__/__/____].

27. Plaintiff has required the following medical treatment:
    ☐ Hospitalization for [____] days
    ☐ Emergency medical treatment
    ☐ Surgery: [________________________________]
    ☐ Ongoing treatment: [________________________________]
    ☐ Medications: [________________________________]
    ☐ Physical therapy
    ☐ Other: [________________________________]

28. Plaintiff's injuries are permanent and have resulted in:
    ☐ Permanent disability
    ☐ Permanent impairment
    ☐ Chronic pain
    ☐ Reduced life expectancy
    ☐ Other: [________________________________]

---

V. FIRST CAUSE OF ACTION: STRICT LIABILITY - DESIGN DEFECT

29. Plaintiff incorporates all preceding paragraphs by reference.

30. Under the Restatement (Third) of Torts: Products Liability Section 6, a prescription drug is defective in design if the foreseeable risks of harm posed by the drug are sufficiently great in relation to its foreseeable therapeutic benefits that reasonable health-care providers, knowing of such foreseeable risks and therapeutic benefits, would not prescribe the drug for any class of patients.

31. The Drug was defective in design because its risks of causing [________________________________] were sufficiently great that no reasonable physician would prescribe it for any class of patients when safer alternative treatments were available.

32. Safer alternative treatments that were available included:
    ☐ [________________________________]
    ☐ [________________________________]

33. The design defect was a direct and proximate cause of Plaintiff's injuries.

---

VI. SECOND CAUSE OF ACTION: STRICT LIABILITY - FAILURE TO WARN

34. Plaintiff incorporates all preceding paragraphs by reference.

35. Under the Restatement (Third) of Torts: Products Liability Section 6(d), a prescription drug is defective if the manufacturer fails to provide reasonable instructions or warnings regarding foreseeable risks of harm to prescribing physicians.

36. Defendants failed to adequately warn physicians, including Plaintiff's prescribing physician, of the risk of [________________________________].

37. The warnings provided by Defendants were inadequate because:
    ☐ No warning was given for this risk
    ☐ The warning was buried in fine print
    ☐ The warning minimized the severity of the risk
    ☐ The warning understated the frequency of the risk
    ☐ The warning was not updated when new data emerged
    ☐ Other: [________________________________]

38. Had adequate warnings been provided, Plaintiff's prescribing physician would not have prescribed the Drug, or would have monitored Plaintiff differently.

39. The failure to warn was a direct and proximate cause of Plaintiff's injuries.

---

VII. THIRD CAUSE OF ACTION: NEGLIGENCE

40. Plaintiff incorporates all preceding paragraphs by reference.

41. Defendants owed a duty of care to Plaintiff to:
    ☐ Design a drug that is reasonably safe
    ☐ Conduct adequate testing before marketing
    ☐ Report adverse events to the FDA
    ☐ Warn physicians and patients of known risks
    ☐ Update warnings when new risks are discovered
    ☐ Comply with FDA regulations

42. Defendants breached their duty of care by:
    ☐ [________________________________]
    ☐ [________________________________]
    ☐ [________________________________]

43. Defendants' negligence was a direct and proximate cause of Plaintiff's injuries.

---

VIII. FOURTH CAUSE OF ACTION: NEGLIGENT MISREPRESENTATION

44. Plaintiff incorporates all preceding paragraphs by reference.

45. Defendants made misrepresentations to the FDA, physicians, and consumers regarding the safety and efficacy of the Drug.

46. These misrepresentations included:
    ☐ [________________________________]
    ☐ [________________________________]

47. Defendants knew or should have known that these representations were false.

48. Plaintiff's prescribing physician and Plaintiff justifiably relied on these misrepresentations.

49. Defendants' misrepresentations were a direct and proximate cause of Plaintiff's injuries.

---

IX. FIFTH CAUSE OF ACTION: BREACH OF EXPRESS WARRANTY

50. Plaintiff incorporates all preceding paragraphs by reference.

51. Defendants expressly warranted that the Drug was safe and effective for the treatment of [________________________________].

52. These warranties were made through:
    ☐ Drug labeling
    ☐ Package inserts
    ☐ Marketing materials
    ☐ Advertising
    ☐ Representations to physicians
    ☐ Other: [________________________________]

53. The Drug did not conform to these express warranties because it was not safe as warranted.

54. The breach of express warranty was a direct and proximate cause of Plaintiff's injuries.

---

X. SIXTH CAUSE OF ACTION: BREACH OF IMPLIED WARRANTY

55. Plaintiff incorporates all preceding paragraphs by reference.

56. By manufacturing and selling the Drug, Defendants impliedly warranted that the Drug was merchantable and fit for its intended purpose.

57. The Drug was not merchantable or fit for its intended purpose because it caused serious harm.

58. The breach of implied warranty caused Plaintiff's injuries.

---

XI. SEVENTH CAUSE OF ACTION: FRAUD AND CONCEALMENT

59. Plaintiff incorporates all preceding paragraphs by reference.

60. Defendants knowingly concealed material facts about the Drug's risks from the FDA, physicians, and patients.

61. The concealed facts included:
    ☐ [________________________________]
    ☐ [________________________________]

62. Defendants had a duty to disclose these facts.

63. Defendants concealed these facts with the intent to induce physicians to prescribe and patients to use the Drug.

64. Plaintiff and Plaintiff's physician relied on Defendants' non-disclosure.

65. Defendants' fraud and concealment caused Plaintiff's injuries.

---

XII. EIGHTH CAUSE OF ACTION: VIOLATION OF CONSUMER PROTECTION LAWS

66. Plaintiff incorporates all preceding paragraphs by reference.

67. Defendants' conduct violated [State] consumer protection laws, including [________________________________].

68. Defendants engaged in unfair and deceptive practices by misrepresenting the Drug's safety.

69. Plaintiff suffered damages as a result of these violations.

---

XIII. DAMAGES

70. As a direct and proximate result of Defendants' conduct, Plaintiff has suffered:

Economic Damages

Category	Amount
Past medical expenses	$[________________________________]
Future medical expenses	$[________________________________]
Past lost wages	$[________________________________]
Future lost earning capacity	$[________________________________]
Other economic losses	$[________________________________]

Non-Economic Damages

• Physical pain and suffering
• Mental anguish and emotional distress
• Loss of enjoyment of life
• Permanent disability and impairment
• Disfigurement
• Loss of consortium

Punitive Damages

71. Defendants' conduct was willful, wanton, malicious, and in conscious disregard of patient safety. Defendants prioritized profits over safety and concealed known risks. Punitive damages are warranted to punish Defendants and deter similar conduct.

---

XIV. PRAYER FOR RELIEF

WHEREFORE, Plaintiff respectfully prays for judgment as follows:

1. Compensatory damages in an amount to be determined at trial;
2. Punitive damages sufficient to punish and deter;
3. Pre-judgment and post-judgment interest;
4. Costs of suit and reasonable attorneys' fees;
5. Such other relief as the Court deems just and proper.

---

XV. JURY DEMAND

Plaintiff demands a trial by jury on all issues so triable.

---

DATED: [__/__/____]

Respectfully submitted,

________________________________________
[Attorney Name]
[Bar Number]
[Law Firm Name]
[Address]
[City, State ZIP]
[Telephone]
[Email]

Attorney for Plaintiff

---

VERIFICATION

STATE OF [________________________________]
COUNTY OF [________________________________]

I, [________________________________], declare under penalty of perjury that I am the Plaintiff in this action, that I have read the foregoing Complaint, and that the facts stated therein are true and correct to the best of my knowledge.

Executed on [__/__/____].

________________________________________
Plaintiff Signature

---

FILING CHECKLIST

☐ Complaint reviewed by experienced pharmaceutical litigation counsel
☐ Verification executed
☐ Filing fee paid or waived
☐ Civil cover sheet completed
☐ Summons prepared for all Defendants
☐ Medical records obtained and reviewed
☐ Expert witness identified (medical causation)
☐ Expert witness identified (pharmaceutical/pharmacology)
☐ FDA records researched (FOIA if necessary)

---

SPECIAL CONSIDERATIONS

Learned Intermediary Doctrine:
In most states, the duty to warn for prescription drugs runs to the prescribing physician, not the patient directly. The complaint should allege that the physician was not adequately warned.

Preemption:
Federal preemption may apply to failure-to-warn claims involving FDA-approved labeling. Consider preemption defenses when drafting.

Multidistrict Litigation:
Many pharmaceutical cases are consolidated into MDL proceedings. Check for pending MDLs involving the same drug.

Statute of Limitations:
Discovery rules may apply - the statute may run from when the injury was or should have been discovered.

---

SOURCES AND REFERENCES

• FDA Drug Information
• FDA Guidance Documents
• 21 CFR - Food and Drugs
• Holland & Knight - FDA 2026 Watch